Effect of Alpha Lipoic Acid on Obesity Related Comorbidities

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00994513
Recruitment Status : Completed
First Posted : October 14, 2009
Last Update Posted : September 24, 2010
Xinjiang Medical University
Information provided by:
Augusta University

Brief Summary:
The major objective of this study is to conduct a double-blind, placebo-controlled, randomized clinical trial to assess whether oral alpha lipoic acid supplementation will decrease cardiovascular disease and type 2 diabetes risk in obese subjects.

Condition or disease Intervention/treatment Phase
Obesity Cardiovascular Disease Type 2 Diabetes Dietary Supplement: Alpha Lipoic Acid Dietary Supplement: Placebo Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Effect of Alpha Lipoic Acid on Obesity Related Comorbidities
Study Start Date : July 2009
Actual Primary Completion Date : May 2010
Actual Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: ALA
alpha lipoic acid 1200 mg/day
Dietary Supplement: Alpha Lipoic Acid
1200 mg/day
Other Name: Lipoic acid

Placebo Comparator: Placebo
placebo 1200 mg/day
Dietary Supplement: Placebo
1200 mg/day

Primary Outcome Measures :
  1. Biomarkers of oxidative stress [ Time Frame: 2 months ]
  2. Insulin sensitivity [ Time Frame: 2 months ]
  3. Endothelial function [ Time Frame: 2 months ]

Secondary Outcome Measures :
  1. Inflammatory markers [ Time Frame: 2 months ]
  2. Blood pressure [ Time Frame: 2 months ]
  3. Fasting lipid profile [ Time Frame: 2 months ]
  4. Pulse wave velocity [ Time Frame: 2 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Han ethnicity
  • BMI≥25kg/m2
  • Having at least one of the following risk factors: borderline hypertension (130mmHg≤SBP<140mmHg or 85mmHg≤DBP<90mmHg), dyslipidemia (fasting total cholesterol ≥240mg/dl or HDL-C<40mg/dl), or impaired fasting glucose (fasting glucose levels between 6.1 and 7.0mmol/L)
  • 18-60 years old
  • Not on any antioxidant vitamin supplement

Exclusion Criteria:

  • Pregnancy, lactation or child-bearing age without birth control device
  • History of hypertension, diabetes, coronary heart disease(CHD), cancer or liver disease
  • Anything that would impede the subject from complying with the ALA treatment
  • History of psychiatric problems

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00994513

China, Xinjiang
Xinjiang Medical University
Urumqi, Xinjiang, China, 830054
Sponsors and Collaborators
Augusta University
Xinjiang Medical University

Responsible Party: Xiaoling Wang, Assistant Professor, Medical College of Georgia Identifier: NCT00994513     History of Changes
Other Study ID Numbers: HAC08-07-02
First Posted: October 14, 2009    Key Record Dates
Last Update Posted: September 24, 2010
Last Verified: September 2010

Keywords provided by Augusta University:

Additional relevant MeSH terms:
Cardiovascular Diseases
Nutrition Disorders
Body Weight
Signs and Symptoms
Thioctic Acid
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Vitamin B Complex
Growth Substances